AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV): $142.90

1.18 (+0.83%)

POWR Rating

Component Grades














  • ABBV scores best on the Quality dimension, with a Quality rank ahead of 97.73% of US stocks.
  • The strongest trend for ABBV is in Quality, which has been heading up over the past 177 days.
  • ABBV ranks lowest in Momentum; there it ranks in the 17th percentile.

ABBV Stock Summary

  • ABBVIE INC's market capitalization of $249,672,906,059 is ahead of 99.55% of US-listed equities.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.59% of US stocks.
  • The volatility of ABBVIE INC's share price is greater than that of just 9.23% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ABBVIE INC are NVO, BABA, PFE, TMO, and LLY.
  • ABBV's SEC filings can be seen here. And to visit ABBVIE INC's official web site, go to

ABBV Valuation Summary

  • In comparison to the median Healthcare stock, ABBV's price/earnings ratio is 2.04% higher, now standing at 20.
  • Over the past 118 months, ABBV's EV/EBIT ratio has gone up 4.4.

Below are key valuation metrics over time for ABBV.

Stock Date P/S P/B P/E EV/EBIT
ABBV 2022-09-23 4.4 17.3 20.0 19.5
ABBV 2022-09-22 4.4 17.3 20.0 19.5
ABBV 2022-09-21 4.3 16.9 19.6 19.2
ABBV 2022-09-20 4.4 17.1 19.8 19.3
ABBV 2022-09-19 4.4 17.2 20.0 19.4
ABBV 2022-09-16 4.4 17.4 20.2 19.6

ABBV Growth Metrics

    The 2 year net income to common stockholders growth rate now stands at 47.93%.
  • Its 3 year net cashflow from operations growth rate is now at 65.29%.
  • Its year over year cash and equivalents growth rate is now at -37.49%.
Over the past 15 months, ABBV's revenue has gone up $7,154,000,000.

The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 57,349 22,923 12,637
2022-03-31 56,725 22,808 12,479
2021-12-31 56,197 22,777 11,542
2021-09-30 55,169 22,556 7,534
2021-06-30 53,729 20,451 6,663
2021-03-31 50,195 18,650 5,159

ABBV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
  • ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
  • PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.

The table below shows ABBV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.369 0.677 0.119
2021-06-30 0.359 0.656 0.102
2021-03-31 0.335 0.648 0.078
2020-12-31 0.339 0.664 0.070
2020-09-30 0.339 0.687 0.131
2020-06-30 0.372 0.736 0.147

ABBV Stock Price Chart Interactive Chart >

Price chart for ABBV

ABBV Price/Volume Stats

Current price $142.90 52-week high $175.91
Prev. close $141.72 52-week low $106.86
Day low $142.62 Volume 305,559
Day high $144.50 Avg. volume 6,808,028
50-day MA $141.58 Dividend yield 3.98%
200-day MA $146.16 Market Cap 252.66B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

3 Dividend Aristocrats In Warren Buffett's Secret Portfolio You Can Buy Right Now

A little-known group of Buffett stocks includes three members of dividend royalty with solid growth prospects.

Yahoo | September 25, 2022

AbbVie Inc.'s (NYSE:ABBV) Business Is Trailing The Market But Its Shares Aren't

With a price-to-earnings (or "P/E") ratio of 20.1x AbbVie Inc. ( NYSE:ABBV ) may be sending bearish signals at the...

Yahoo | September 24, 2022

Is AbbVie a Buy?

Drugmaker AbbVie (NYSE: ABBV) is one of the largest healthcare stocks in the world, with a market cap of over $250 billion. AbbVie last reported its earnings in July. Humira remains key to AbbVie's business for now, generating $5.4 billion this past quarter, nearly three times the $1.8 billion Skyrizi and Rinvoq generated.

Yahoo | September 24, 2022

Healthcare Learned a Lot From Covid. 12 Ways to Invest Now.

From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.

Yahoo | September 23, 2022

Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond

Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.

Yahoo | September 23, 2022

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo 5.30%
3-mo -5.83%
6-mo -10.58%
1-year 38.58%
3-year 120.33%
5-year 102.20%
YTD 8.55%
2021 32.43%
2020 27.72%
2019 1.47%
2018 -0.96%
2017 60.08%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.776 seconds.